These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 1460673)

  • 1. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
    Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
    J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
    Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
    Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Groot K; Halmos G
    Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
    Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.
    Szepeshazi K; Schally AV; Halmos G; Lamharzi N; Groot K; Horvath JE
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10913-8. PubMed ID: 9380734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
    Shirahige Y; Cai RZ; Szepeshazi K; Halmos G; Pinski J; Groot K; Schally AV
    Biomed Pharmacother; 1994; 48(10):465-72. PubMed ID: 7858155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
    Radulovic S; Schally AV; Reile H; Halmos G; Szepeshazi K; Groot K; Milovanovic S; Miller G; Yano T
    Acta Oncol; 1994; 33(6):693-701. PubMed ID: 7946450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
    Szepesházi K; Halmos G; Schally AV; Arencibia JM; Groot K; Vadillo-Buenfil M; Rodriguez-Martin E
    J Cancer Res Clin Oncol; 1999; 125(8-9):444-52. PubMed ID: 10480336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
    Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.
    Miyazaki M; Lamharzi N; Schally AV; Halmos G; Szepeshazi K; Groot K; Cai RZ
    Eur J Cancer; 1998 Apr; 34(5):710-7. PubMed ID: 9713279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
    Radulovic S; Miller G; Schally AV
    Cancer Res; 1991 Nov; 51(21):6006-9. PubMed ID: 1682040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR; Radulovic S; Groot K; Schally AV
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
    Koppán M; Halmos G; Arencibia JM; Lamharzi N; Schally AV
    Cancer; 1998 Oct; 83(7):1335-43. PubMed ID: 9762934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
    Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L
    Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
    Halmos G; Schally AV
    Proc Natl Acad Sci U S A; 1997 Feb; 94(3):956-60. PubMed ID: 9023364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM
    Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.